Figure 6

(A) Pie-chart represents the CYP2C9*2 and (B) CYP2C9*3 polymorphisms observed in some of the Middle Eastern countries. (C) The percentage of CYP2C9*2 and CYP2C9*3 polymorphisms identified in Oman, Egypt, Lebanon, as well as in Al-Ahsa, Riyadh and Jeddah regions of the KSA. The incidence of CYP2C9 polymorphisms in Saudi population was similar to Caucasians; but, it was more than Asians and Africans [169] and adverse bleeding episodes are not uncommon in Saudi patients with CYP2C9*2 and CYP2C*3 alleles and may require 40% less Warfarin dose to induce effective anti-coagulation [169].